Long-term risk of cancer in membranous nephropathy patients, Am J Kidney Dis, vol.50, pp.396-403, 2007. ,
Onco-nephrology: Glomerular diseases with cancer, Clin J Am Soc Nephrol, vol.7, pp.1701-1712, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00919120
Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association, Kidney Int, vol.70, pp.1510-1517, 2006. ,
A proposal for a serology-based approach to membranous nephropathy, J Am Soc Nephrol, vol.28, pp.421-430, 2017. ,
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy, Kidney Int, vol.95, pp.666-679, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02380896
Circulating antibodies against thrombospondin type-I domaincontaining 7A in Chinese patients with idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.12, pp.1642-1651, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02193806
A mechanism for cancer-associated membranous nephropathy, N Engl J Med, vol.374, 1995. ,
, Cohen Tervaert JW
, Limburg Renal Registry: Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy, Am J Kidney Dis, vol.62, pp.1223-1225, 2013.
A follow-up analysis of positron emission tomography/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy, Oncotarget, vol.7, pp.9645-9651, 2016. ,
Solnes LB: Whole-body 18 F-FDG PET and 18 F-FDG PET/CT in patients with suspected paraneoplastic syndrome: A systematic review and Meta-analysis of diagnostic accuracy, J Nucl Med, vol.58, pp.1031-1036, 2017. ,